$TGTX News Article - TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 75th Annual Meeting
https://marketwirenews.com/news-releases/tg-t...22761.html